{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.5","value":"2980"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state.","dispersionType":"Standard Deviation","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in Part 2 TGA and TGB","id":"OG000","title":"12mg QD INCB057643"}],"paramType":"MEAN","populationDescription":"PK evaluable population includes all subjects who received at least 1 dose of study drug and had at least 1 PK sample collected and analyzed","reportingStatus":"POSTED","timeFrame":"C2D1","title":"AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy","type":"SECONDARY","unitOfMeasure":"h*nM"}